Payment overview · 2025
General Payments
$2,995.21
57 reported records · 20 companies
Healthcare provider profile · identity verified
Asim Yousuf, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SCHENECTADY, NY · NPI 1972532976
Verified facts
What the public records show
CMS Open Payments records show Asim Yousuf, MD received $2,995.21 in general payments during 2025 across 57 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $693.68 | 23.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $686.43 | 22.9% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $208.90 | 7.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $205.71 | 6.9% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $146.70 | 4.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $131.40 | 4.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $129.25 | 4.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $125.01 | 4.2% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 4.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 4.2% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $121.84 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $82.62 | 2.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.72 | 1.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.34 | 1.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.49 | 1.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.94 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.39 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.44 | 0.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.55 | 0.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $13.81 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,995.21 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $396.90 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $244.54 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $208.90 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $206.52 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $146.70 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $142.66 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $131.40 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $129.25 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $122.88 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $107.03 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.03 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $93.78 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $82.62 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 90 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 82 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 72 | 34 |
| Eliquis | Apixaban | 68 | 33 |
| Omeprazole | Omeprazole | 65 | 28 |
| Cefuroxime | Cefuroxime Axetil | 62 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 34 |
| Losartan Potassium | Losartan Potassium | 58 | 26 |
| Prednisone | Prednisone | 57 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 19 |
| Azithromycin | Azithromycin | 40 | 20 |
| Cephalexin | Cephalexin | 40 | 30 |
| Lisinopril | Lisinopril | 39 | 20 |
| Furosemide | Furosemide | 35 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | 12 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | 15 |
| Torsemide | Torsemide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | 11 |
| Potassium Chloride | Potassium Chloride | 17 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | 14 |
| Allopurinol | Allopurinol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | 11 |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,995.21 · 57 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AVYCAZ, BREZTRI, CARVYKTI, Cologuard Collection Kit, DALVANCE, EMBLAVEO, FANAPT, FARXIGA, INVEGA SUSTENNA, JARDIANCE, KRYSTEXXA, Kerendia, NURTEC ODT, Ohtuvayre, Omnipod, Ozempic, PAXLOVID, QULIPTA, Qelbree, REXULTI, RYBREVANT, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Vafseo, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error